Vanessa Carle - 31 Jul 2024 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
Secretary
Signature
/Vanessa Carle/
Issuer symbol
LEXX
Transactions as of
31 Jul 2024
Net transactions value
-$10,268
Form type
4
Filing time
01 Aug 2024, 12:25:52 UTC
Previous filing
15 May 2024
Next filing
16 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LEXX common shares Sale $10,268 -2,567 -100% $4.00 0 31 Jul 2024 Direct
holding LEXX common shares 2,567 31 Jul 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LEXX Warrants 67 31 Jul 2024 Common Shares 67 $36.00 Direct
holding LEXX Stock Options 12,567 31 Jul 2024 Common Shares 12,500 $3.00 Direct F1
holding LEXX Stock Options 17,567 31 Jul 2024 Common Shares 5,000 $3.00 Direct F2
holding LEXX Stock Options 27,567 31 Jul 2024 Common Shares 10,000 $3.00 Direct F3
holding LEXX Stock Options 40,067 31 Jul 2024 Common Shares 12,500 $2.91 Direct
holding LEXX Stock Options 50,067 31 Jul 2024 Common Shares 10,000 $1.15 Direct
holding LEXX Stock Options 60,067 31 Jul 2024 Common Shares 10,000 $2.36 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Repriced from $5.31 pursuant to shareholder approval received May 9,2023
F2 Repriced from $7.08 pursuant to shareholder approval received May 9, 2023
F3 Repriced from $6.23 pursuant to shareholder approval received May 9, 2023